Cargando…

Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma

BACKGROUND: Copper-induced cell death has been widely investigated in human diseases as a form of programmed cell death (PCD). The newly recognized mechanism underlying copper-induced cell death provided us creative insights into the copper-related toxicity in cells, and this form of PCD was termed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bao, Song, Qiang, Wei, Yuang, Wu, Xiangzheng, Han, Tian, Bu, Hengtao, Tang, Sensheng, Qian, Jian, Shao, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582538/
https://www.ncbi.nlm.nih.gov/pubmed/36275737
http://dx.doi.org/10.3389/fimmu.2022.948042
_version_ 1784812862328274944
author Wang, Bao
Song, Qiang
Wei, Yuang
Wu, Xiangzheng
Han, Tian
Bu, Hengtao
Tang, Sensheng
Qian, Jian
Shao, Pengfei
author_facet Wang, Bao
Song, Qiang
Wei, Yuang
Wu, Xiangzheng
Han, Tian
Bu, Hengtao
Tang, Sensheng
Qian, Jian
Shao, Pengfei
author_sort Wang, Bao
collection PubMed
description BACKGROUND: Copper-induced cell death has been widely investigated in human diseases as a form of programmed cell death (PCD). The newly recognized mechanism underlying copper-induced cell death provided us creative insights into the copper-related toxicity in cells, and this form of PCD was termed cuproptosis. METHODS: Through consensus clustering analysis, ccRCC patients from TCGA database were classified into different subgroups with distinct cuproptosis-based molecular patterns. Analyses of clinical significance, long-term survival, and immune features were performed on subgroups accordingly. The cuproptosis-based risk signature and nomogram were constructed and validated relying on the ccRCC cohort as well. The cuproptosis scoring system was generated to better characterize ccRCC patients. Finally, in vitro validation was conducted using ccRCC clinical samples and cell lines. RESULT: Patients from different subgroups displayed diverse clinicopathological features, survival outcomes, tumor microenvironment (TME) characteristics, immune-related score, and therapeutic responses. The prognostic model and cuproptosis score were well validated and proved to efficiently distinguish the high risk/score and low risk/score patients, which revealed the great predictive value. The cuproptosis score also tended out to be intimately associated with the prognosis and immune features of ccRCC patients. Additionally, the hub cuproptosis-associated gene (CAG) FDX1 presented a dysregulated expression pattern in human ccRCC samples, and it was confirmed to effectively promote the killing effects of copper ionophore elesclomol as a direct target. In vitro functional assays revealed the prominent anti-cancer role of FDX1 in ccRCC. CONCLUSION: Cuproptosis played an indispensable role in the regulation of TME features, tumor progression, and long-term prognosis of ccRCC.
format Online
Article
Text
id pubmed-9582538
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95825382022-10-21 Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma Wang, Bao Song, Qiang Wei, Yuang Wu, Xiangzheng Han, Tian Bu, Hengtao Tang, Sensheng Qian, Jian Shao, Pengfei Front Immunol Immunology BACKGROUND: Copper-induced cell death has been widely investigated in human diseases as a form of programmed cell death (PCD). The newly recognized mechanism underlying copper-induced cell death provided us creative insights into the copper-related toxicity in cells, and this form of PCD was termed cuproptosis. METHODS: Through consensus clustering analysis, ccRCC patients from TCGA database were classified into different subgroups with distinct cuproptosis-based molecular patterns. Analyses of clinical significance, long-term survival, and immune features were performed on subgroups accordingly. The cuproptosis-based risk signature and nomogram were constructed and validated relying on the ccRCC cohort as well. The cuproptosis scoring system was generated to better characterize ccRCC patients. Finally, in vitro validation was conducted using ccRCC clinical samples and cell lines. RESULT: Patients from different subgroups displayed diverse clinicopathological features, survival outcomes, tumor microenvironment (TME) characteristics, immune-related score, and therapeutic responses. The prognostic model and cuproptosis score were well validated and proved to efficiently distinguish the high risk/score and low risk/score patients, which revealed the great predictive value. The cuproptosis score also tended out to be intimately associated with the prognosis and immune features of ccRCC patients. Additionally, the hub cuproptosis-associated gene (CAG) FDX1 presented a dysregulated expression pattern in human ccRCC samples, and it was confirmed to effectively promote the killing effects of copper ionophore elesclomol as a direct target. In vitro functional assays revealed the prominent anti-cancer role of FDX1 in ccRCC. CONCLUSION: Cuproptosis played an indispensable role in the regulation of TME features, tumor progression, and long-term prognosis of ccRCC. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9582538/ /pubmed/36275737 http://dx.doi.org/10.3389/fimmu.2022.948042 Text en Copyright © 2022 Wang, Song, Wei, Wu, Han, Bu, Tang, Qian and Shao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Bao
Song, Qiang
Wei, Yuang
Wu, Xiangzheng
Han, Tian
Bu, Hengtao
Tang, Sensheng
Qian, Jian
Shao, Pengfei
Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma
title Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma
title_full Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma
title_fullStr Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma
title_full_unstemmed Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma
title_short Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma
title_sort comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582538/
https://www.ncbi.nlm.nih.gov/pubmed/36275737
http://dx.doi.org/10.3389/fimmu.2022.948042
work_keys_str_mv AT wangbao comprehensiveinvestigationintocuproptosisinthecharacterizationofclinicalfeaturesmolecularcharacteristicsandimmunesituationsofclearcellrenalcellcarcinoma
AT songqiang comprehensiveinvestigationintocuproptosisinthecharacterizationofclinicalfeaturesmolecularcharacteristicsandimmunesituationsofclearcellrenalcellcarcinoma
AT weiyuang comprehensiveinvestigationintocuproptosisinthecharacterizationofclinicalfeaturesmolecularcharacteristicsandimmunesituationsofclearcellrenalcellcarcinoma
AT wuxiangzheng comprehensiveinvestigationintocuproptosisinthecharacterizationofclinicalfeaturesmolecularcharacteristicsandimmunesituationsofclearcellrenalcellcarcinoma
AT hantian comprehensiveinvestigationintocuproptosisinthecharacterizationofclinicalfeaturesmolecularcharacteristicsandimmunesituationsofclearcellrenalcellcarcinoma
AT buhengtao comprehensiveinvestigationintocuproptosisinthecharacterizationofclinicalfeaturesmolecularcharacteristicsandimmunesituationsofclearcellrenalcellcarcinoma
AT tangsensheng comprehensiveinvestigationintocuproptosisinthecharacterizationofclinicalfeaturesmolecularcharacteristicsandimmunesituationsofclearcellrenalcellcarcinoma
AT qianjian comprehensiveinvestigationintocuproptosisinthecharacterizationofclinicalfeaturesmolecularcharacteristicsandimmunesituationsofclearcellrenalcellcarcinoma
AT shaopengfei comprehensiveinvestigationintocuproptosisinthecharacterizationofclinicalfeaturesmolecularcharacteristicsandimmunesituationsofclearcellrenalcellcarcinoma